Cargando…

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

BACKGROUND: ACAM2000, a thymidine kinase (TK)-positive strain of vaccinia virus, is the current smallpox vaccine in the US. Preclinical testing demonstrated potent oncolytic activity of ACAM2000 against several tumor types. This Phase I clinical trial of ACAM2000 delivered by autologous adipose stro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minev, Boris R., Lander, Elliot, Feller, John F., Berman, Mark, Greenwood, Bernadette M., Minev, Ivelina, Santidrian, Antonio F., Nguyen, Duong, Draganov, Dobrin, Killinc, Mehmet O., Vyalkova, Anna, Kesari, Santosh, McClay, Edward, Carabulea, Gabriel, Marincola, Francesco M., Butterfield, Lisa H., Szalay, Aladar A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699108/ https://www.ncbi.nlm.nih.gov/pubmed/31426803 http://dx.doi.org/10.1186/s12967-019-2011-3

Ejemplares similares

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
por: Draganov, Dobrin D., et al.
Publicado: (2019)

Correction to: Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
por: Draganov, Dobrin D., et al.
Publicado: (2021)

The ratio of ADSCs to HSC-progenitors in adipose tissue derived SVF may provide the key to predict the outcome of stem-cell therapy
por: Kilinc, Mehmet Okyay, et al.
Publicado: (2018)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy
por: Nguyen, Duong Hoang, et al.
Publicado: (2022)

Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells
por: Kilinc, Mehmet Okyay, et al.
Publicado: (2016)

Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells
por: Wang, Huiqiang, et al.
Publicado: (2012)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis
por: Tsoneva, Desislava, et al.
Publicado: (2017)

Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy
por: Huang, Ting, et al.
Publicado: (2015)

Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a “Trojan Horse” in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas
por: Petrov, Ivan, et al.
Publicado: (2020)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice
por: Hofmann, Elisabeth, et al.
Publicado: (2014)

Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice
por: Chen, Nanhai G, et al.
Publicado: (2011)

Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps
por: Kober, Christina, et al.
Publicado: (2015)

Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models
por: Cecil, Alexander, et al.
Publicado: (2019)

Optical Detection and Virotherapy of Live Metastatic Tumor Cells in Body Fluids with Vaccinia Strains
por: Wang, Huiqiang, et al.
Publicado: (2013)

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
por: Worschech, Andrea, et al.
Publicado: (2009)

Intratumoral INF-γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer
por: Kober, Christina, et al.
Publicado: (2015)

Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
por: Gentschev, Ivaylo, et al.
Publicado: (2012)

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
por: Ascierto, Maria Libera, et al.
Publicado: (2011)

The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation
por: Zhang, Qian, et al.
Publicado: (2009)

Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody
por: Patil, Sandeep S., et al.
Publicado: (2012)

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
por: Adelfinger, Marion, et al.
Publicado: (2015)

Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy
por: Haddad, Dana, et al.
Publicado: (2016)

Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68
por: Ehrig, Klaas, et al.
Publicado: (2013)

Oncolytic Viruses
por: Chen, Nanhai G., et al.
Publicado: (2012)

Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection
por: Weibel, Stephanie, et al.
Publicado: (2011)

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2010)

Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2010)

Overcoming tumor immune evasion with an unique arbovirus
por: Lyday, Bruce, et al.
Publicado: (2015)

Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice
por: Donat, Ulrike, et al.
Publicado: (2012)

Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter
por: Haddad, Dana, et al.
Publicado: (2012)

Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2011)

Oncolytic Virotherapy of Canine and Feline Cancer
por: Gentschev, Ivaylo, et al.
Publicado: (2014)

Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy
por: Adelfinger, Marion, et al.
Publicado: (2014)

Theranostic Potential of Oncolytic Vaccinia Virus
por: Rojas, Juan J, et al.
Publicado: (2012)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Oncolytic properties of non-vaccinia poxviruses
por: Ricordel, Marine, et al.
Publicado: (2018)

Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus
por: Haddad, Dana, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_v0a8d09nncus18u5deeqfc5n9i